WFUBMC To Establish Prostate Cancer Center Of Excellence

February 08, 1999

WINSTON-SALEM, N.C. -- Wake Forest University Baptist Medical Center will establish a Center of Excellence for Prostate Cancer this year, making it one of a handful of dedicated centers in the nation committed to the treatment of this disease.

The center is the first of several academic excellence block grant programs the hospital will award over the next several years, as part of a $30 million initiative that is unique among academic medical centers nationwide.

The Prostate Cancer Center of Excellence will focus on improving outcomes for patients, offering hope to the more than 10,000 men in North Carolina alone who will be diagnosed with the disease in 1999.

The $5 million grant from N.C. Baptist Hospitals, Inc., will fund several new positions, including a molecular scientist and epidemiologist, new labs and supplies, and a number of new studies addressing both the prevention and treatment aspects of prostate cancer.

Prostate cancer is the most common type of cancer affecting men in the United States and is the second-highest cause of mortality in American men. Only a few institutions in the nation have programs dedicated to prostate cancer.

"North Carolina Baptist Hospital recognizes that programs like these are necessary to advance the understanding of a disease and thereby to improve diagnosis and treatment," said Len B. Preslar Jr., hospital president and CEO. "By funding these block grants, physicians are enabled to more effectively fight illnesses like prostate cancer and improve outcomes for residents in North Carolina, as well as nationwide."

Two additional academic excellence block grant proposals will be proposed this spring for funding.

"To be selected for funding the proposed program must be multidisciplinary, and should have the capability of elevating the center to one of the top 10 programs of its type in the country," said Curt Furberg, M.D., Ph.D., director of the Office of Academic Program Development for the Medical Center. "In addition, the programs should contain education, both basic and clinical research, and clinical care initiatives."

Budgets for these block grant programs will not exceed $5 million -- $2.5 million of which will be set aside in an escrow account for future growth of the program.

"One of the goals of this type of program is to take good research and make it outstanding," said Richard H. Dean, M.D., senior vice president for health affairs of Wake Forest University Baptist Medical Center. "This is a remarkable program that will affect patient care and our community positively over the next decade."

For example, the Prostate Cancer Center for Excellence plans to provide new treatment and quality-of-life protocols, as well as developing new methods to treat the disease.

Research will include basic scientists working on chemoprevention. Epidemiological studies will focus on farmers, African-Americans and other high-risk individuals and on diet-gene interactions, such as the effects of fruits and vegetables and decreasing dietary fat.

Nutritional studies on new treatments including gene therapy, immunotherapy, hormone treatments and new drug therapies will also be included.

"One of the criteria for receiving a block grant is to provide a program which treats all aspects of patient care," Furberg said. "We want our centers of excellence to not only look at new treatment procedures, but quality-of-life issues as well."

Wake Forest Baptist Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to